Identification of new regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Peachman, Kristina K ^a,b   Karasavvas, Nicos ^c   Chenine, Agnes Laurence ^a,b   McLinden, Robert ^a,b   Rerks Ngarm, Supachai ^d   Jaranit, Kaewkungwal ^e   Nitayaphan, Sorachai ^f   Pitisuttithum, Punnee ^e   Tovanabutra, Sodsai ^a,b   Zolla Pazner, Susan ^g,h   Michael, Nelson L ^a   Kim, Jerome H ^a,i   Alving, Carl R ^a   Rao, Mangala ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

^c US Army Medical Command   (United States)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Royal Thai Army   (Thailand)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ International Vaccine Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; INTEGRIN RECEPTOR; INTEGRIN RECEPTOR ALPHA4BETA7; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ACT 1; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; UNCLASSIFIED DRUG; V2 INTEGRIN MONOCLONAL ANTIBODY; V2 PEPTIDE MONOCLONAL ANTIBODY; V3 SPECIFIC MONOCLONAL ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INTEGRIN; INTEGRIN ALPHA4BETA7; PROTEIN BINDING;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; B-CELL LYMPHOMA CELL LINE; BINDING AFFINITY; BINDING SITE; CD4+ T LYMPHOCYTE; CELL SURFACE; COMPETITIVE INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCUBATION TIME; INFECTIOUS MOLECULAR CLONE; LDI V MOTIF; MOLECULAR CLONING; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RPMI8866 CELL LINE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VARIABLE 2 LOOP; VARIABLE 3 LOOP; VIRION; AMINO ACID SEQUENCE; CASE CONTROL STUDY; CELL LINE; CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PHASE 3 CLINICAL TRIAL; PROCEDURES; SERODIAGNOSIS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; INTEGRINS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN BINDING;

EID: 84961356295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143895     Document Type: Article

References (69)

1. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366(14):1275-86. doi: 10.1056/NEJMoa1113425
2. Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One. 2013; 8(9):e75665. doi: 10.1371/journal.pone.0075665
3. Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014; 9(2):e87572. doi: 10.1371/journal.pone.0087572
4. Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One. 2013; 8(1):e53629. doi: 10.1371/journal.pone.0053629
5. Zolla-Pazner S, Edlefsen PT, Rolland M, Kong XP, deCamp A, Gottardo R, et al. Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. EBioMedicine. 2014; 1(1):37-45. doi: 10.1016/j.ebiom.2014.10.022
6. Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012; 28(11):1444-57. doi: 10.1089/aid.2012.0103
7. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014; 6(228):228ra39. doi: 10.1126/scitranslmed.3007730
8. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008; 9(3):301-9. doi: 10.1038/ni1566 .
9. Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A. 2009; 106(49):20877-82. doi: 10.1073/pnas.0911796106
10. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002; 110(6):673-87. .
11. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996; 272(5258):60-6. .
12. Luo BH, Springer TA. Integrin structures and conformational signaling. Curr Opin Cell Biol. 2006; 18 (5):579-86. doi: 10.1016/j.ceb.2006.08.005
13. Yu Y, Zhu J, Mi LZ, Walz T, Sun H, Chen J, et al. Structural specializations of alpha(4)beta(7), an integrin that mediates rolling adhesion. J Cell Biol. 2012; 196(1):131-46. doi: 10.1083/jcb.201110023
14. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med. 2004; 199(2):283-93. doi: 10.1084/jem.20030648
15. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, et al. The immunological synapse. Annu Rev Immunol. 2001; 19:375-96. doi: 10.1146/annurev.immunol.19.1.375 .
16. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol. 2005; 5 (10):783-92. doi: 10.1038/nri1705 .
17. Rao M, Peachman KK, Kim J, Gao G, Alving CR, Michael NL, et al. HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. Curr HIV Res. 2013; 11(5):427-38.
18. Danner R, Chaudhari SN, Rosenberger J, Surls J, Richie TL, Brumeanu TD, et al. Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells. PLoS One. 2011; 6(5):e19826. doi: 10.1371/journal.pone.0019826
19. Allam A, Majji S, Peachman K, Jagodzinski L, Kim J, Ratto-Kim S, et al. TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1. Sci Rep. 2015; 5:10443. doi: 10.1038/srep10443 .
20. Ansari AA, Reimann KA, Mayne AE, Takahashi Y, Stephenson ST, Wang R, et al. Blocking of alpha4-beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol. 2011; 186 (2):1044-59. doi: 10.4049/jimmunol.1003052
21. Martinelli E, Veglia F, Goode D, Guerra-Perez N, Aravantinou M, Arthos J, et al. The frequency of alpha (4)beta(7)(high) memory CD4(+) T cells correlates with susceptibility to rectal simian immunodeficiency virus infection. J Acquir Immune Defic Syndr. 2013; 64(4):325-31. doi: 10.1097/QAI. 0b013e31829f6e1a
22. Byrareddy SN, Kallam B, Arthos J, Cicala C, Nawaz F, Hiatt J, et al. Targeting alpha4beta7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-Associated lymphoid tissue from infection. Nat Med. 2014; 20(12):1397-400. doi: 10.1038/nm.3715
23. Cicala C, Arthos J, Fauci AS. HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. Journal of Translational Medicine. 2010; 9(Suppl 1).
24. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012; 206(3):431-41. doi: 10.1093/infdis/jis367
25. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012; 482(7383):89-93. doi: 10. 1038/nature10766
26. Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol. 2013; 87(3):1708-19. doi: 10.1128/JVI.02544-12
27. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209-20. doi: 10.1056/NEJMoa0908492 .
28. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002; 46(6):1896-905.
29. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929):307-12. doi: 10.1038/nature01470 .
30. McLinden RJ, Labranche CC, Chenine AL, Polonis VR, Eller MA, Wieczorek L, et al. Detection of HIV-1 neutralizing antibodies in a human CD4(+)/CXCR4(+)/CCR5(+) T-lymphoblastoid cell assay system. PLoS One. 2013; 8(11):e77756. doi: 10.1371/journal.pone.0077756
31. Chenine AL, Wieczorek L, Sanders-Buell E, Wesberry M, Towle T, Pillis DM, et al. Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01-AE backbone. PLoS One. 2013; 8(11):e76104. Epub 2013/12/07. doi: 10.1371/journal.pone.0076104 PONE-D-13-17876 [pii].
32. Jobe O, Peachman KK, Matyas GR, Asher LV, Alving CR, Rao M. An anti-phosphoinositide-specific monoclonal antibody that neutralizes HIV-1 infection of human monocyte-derived macrophages. Virology. 2012; 430(2):110-9. doi: 10.1016/j.virol.2012.04.017 .
33. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013; 38(1):176-86. doi: 10.1016/j.immuni.2012.11.011
34. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-Alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009; 330(3):864-75. doi: 10.1124/jpet.109. 153973 .
35. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012; 490(7420):417-20. doi: 10.1038/nature11519
36. Upadhyay C, Mayr LM, Zhang J, Kumar R, Gorny MK, Nadas A, et al. Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope. J Virol. 2014; 88 (21):12853-65. doi: 10.1128/JVI.02125-14
37. Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol. 1994; 68(12):8312-20.
38. Swetnam J, Shmelkov E, Zolla-Pazner S, Cardozo T. Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes. PLoS One. 2010; 5(12):e15994. doi: 10.1371/journal. pone.0015994
39. Cicala C, Arthos J, Fauci AS. HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med. 2011; 9 Suppl 1:S2. doi: 10.1186/1479-5876-9-S1-S2
40. Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K, McNally JP, et al. The genotype of early-Transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog. 2011; 7(2):e1001301. doi: 10.1371/journal.ppat. 1001301
41. Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog. 2012; 8(5):e1002686. doi: 10.1371/journal.ppat. 1002686
42. Perez LG, Chen H, Liao HX, Montefiori DC. Envelope glycoprotein binding to the integrin alpha4beta7 is not a general property of most HIV-1 strains. J Virol. 2014; 88(18):10767-77. doi: 10.1128/JVI. 03296-13
43. Nakamura GR, Fonseca DP, O'Rourke SM, Vollrath AL, Berman PW. Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of alpha4beta7 binding. PLoS One. 2012; 7(6):e39045. doi: 10.1371/journal.pone.0039045
44. Tassaneetrithep B, Tivon D, Swetnam J, Karasavvas N, Michael NL, Kim JH, et al. Cryptic determinant of alpha4beta7 binding in the V2 loop of HIV-1 gp120. PLoS One. 2014; 9(9):e108446. doi: 10.1371/journal.pone.0108446
45. Arthos J, Deen KC, Chaikin MA, Fornwald JA, Sathe G, Sattentau QJ, et al. Identification of the residues in human CD4 critical for the binding of HIV. Cell. 1989; 57(3):469-81. .
46. Richardson SI, Gray ES, Mkhize NN, Sheward DJ, Lambson BE, Wibmer CK, et al. South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on alpha4beta7 for replication. Retrovirology. 2015; 12:54. doi: 10.1186/s12977-015-0183-3
47. Pauls E, Ballana E, Moncunill G, Bofill M, Clotet B, Ramo-Tello C, et al. Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. AIDS. 2009; 23(2):266-8. .
48. Cimbro R, Gallant TR, Dolan MA, Guzzo C, Zhang P, Lin Y, et al. Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity. Proc Natl Acad Sci U S A. 2014; 111(8):3152-7. doi: 10.1073/pnas.1314718111
49. Totrov M. Estimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant. PLoS One. 2014; 9(4):e94002. doi: 10.1371/journal.pone.0094002
50. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011; 480(7377):336-43. doi: 10.1038/nature10696
51. Yu Y, Schurpf T, Springer TA. How natalizumab binds and antagonizes alpha4 integrins. J Biol Chem. 2013; 288(45):32314-25. doi: 10.1074/jbc.M113.501668
52. Mayr LM, Cohen S, Spurrier B, Kong XP, Zolla-Pazner S. Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. PLoS One. 2013; 8 (7):e70859. doi: 10.1371/journal.pone.0070859
53. Spurrier B, Sampson J, Gorny MK, Zolla-Pazner S, Kong XP. Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV. J Virol. 2014; 88 (8):4100-12. doi: 10.1128/JVI.03153-13
54. Carrow EW, Vujcic LK, Glass WL, Seamon KB, Rastogi SC, Hendry RM, et al. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. AIDS Res Hum Retroviruses. 1991; 7(10):831-8. .
55. Krachmarov CP, Kayman SC, Honnen WJ, Trochev O, Pinter A. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2001; 17(18):1737-48. doi: 10.1089/08892220152741432 .
56. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009; 458 (7238):636-40. doi: 10.1038/nature07930 .
57. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One. 2010; 5(1):e8805. doi: 10.1371/journal.pone.0008805
58. Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, et al. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol. 2010; 17(8):955-61. doi: 10.1038/nsmb.1861 .
59. Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, et al. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res Hum Retroviruses. 2004; 20(11):1254-8. doi: 10.1089/0889222042545054 .
60. Stanfield RL, Gorny MK, Zolla-Pazner S, Wilson IA. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J Virol. 2006; 80(12):6093-105. doi: 10.1128/JVI.00205-06
61. Shotton C, Arnold C, Sattentau Q, Sodroski J, McKeating JA. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol. 1995; 69(1):222-30.
62. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013; 342(6165):1484-90. doi: 10.1126/science.1245627
63. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013; 342(6165):1477-83. doi: 10.1126/science.1245625
64. Bartesaghi A, Merk A, Borgnia MJ, Milne JL, Subramaniam S. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol. 2013; 20 (12):1352-7. doi: 10.1038/nsmb.2711
65. Khayat R, Lee JH, Julien JP, Cupo A, Klasse PJ, Sanders RW, et al. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol. 2013; 87(17):9865-72. doi: 10.1128/JVI. 01222-13
66. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature. 2008; 455(7209):109-13. Epub 2008/08/01. doi: 10.1038/nature07159 nature07159 [pii].
67. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, et al. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 2010; 6(12):e1001249. doi: 10.1371/journal.ppat.1001249
68. Meyerson JR, White TA, Bliss D, Moran A, Bartesaghi A, Borgnia MJ, et al. Determination of molecular structures of HIV envelope glycoproteins using cryo-electron tomography and automated sub-Tomogram averaging. J Vis Exp. 2011;(58: ). doi: 10.3791/2770
69. Li C, Jin W, Du T, Wu B, Liu Y, Shattock RJ, et al. Binding of HIV-1 virions to alpha4beta 7 expressing cells and impact of antagonizing alpha4beta 7 on HIV-1 infection of primary CD4+ T cells. Virol Sin. 2014; 29(6):381-92. doi: 10.1007/s12250-014-3525-8